NASDAQ · Biotechnology · USD
Cingulate Inc. (CING) Stock Analysis
Cingulate Inc. (CING) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CING Key Statistics
As of Oct 21, 2026Trading
- Open
- $4.53
- Previous Close
- $4.53
- Day's Range
- 4.50–4.70
- 52-Week Range
- 3.16–11.89
- Volume
- 132.10K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- −0.88
Valuation
- Market Cap
- $68.64M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −3.51
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$22.45M
- Shares Outstanding
- 14.54M
- 1-Year Return
- +21.04%
Dividend and dates
- Avg Volume
- 128.54K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CING closed at $4.66, +21.04% over 1 year.
Cingulate Inc. (CING) has a market capitalization of $68.64M.
In fiscal 2025, CING reported revenue of $0.00.
CING Stock Return by Calendar Year
Cingulate Inc. (CING) return since Dec 2021: what $10,000 became
- 1 year
- $10,000 $12,104
- +21.04%
- 3 years
- $10,000 $413
- −95.87%
- Since Dec 2021
- $10,000 $44
- −99.56%
If you had invested $10,000 in Cingulate Inc. (CING) at the close on December 8, 2021, the earliest close on record here, it would have been worth $44 at the close on October 21, 2026: −99.56% in total, −67.25% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +7.37% |
| 2025 | −11.97% |
| 2024 | −94.63% |
| 2023 | −61.75% |
| 2022 | −63.77% |
| 2021 (partial year) | −37.98% |
As of October 21, 2026.
CING Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$22.45M | — |
| 2024 | $0.00 | −$16.56M | — |
| 2023 | $0.00 | −$23.53M | — |
| 2022 | $0.00 | −$17.68M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$19.94M | −$22.45M | — |
| 2024 | $0.00 | — | −$15.65M | −$16.56M | — |
| 2023 | $0.00 | — | −$22.76M | −$23.53M | — |
| 2022 | $0.00 | — | −$17.50M | −$17.68M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
YahooRoth Capital Reiterates Buy on Cingulate, Lowers Price Target to $9
BenzingaAscendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $44
BenzingaCingulate Q2 EPS $(0.45) Beats $(0.63) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B